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Introduction
Cancer is defined as an abnormal growth and replication 
of cells, which interferes with normal physiology and 
function of the tissues and the body.1 Brain tumors are 
also a mass of unnecessary cells growing in the brain, 
which can be divided into two main groups. Primary 
brain tumors: tumors that originate from brain’s tissues.
Secondary brain tumors: which originate from other 
organs in the body and migrate to brain following 
metastasis.2-4
Primary brain tumors are classified as benign and 
malignant. Benign tumor cells have a slow proliferation 
rate, are rarely invasive with frequently normal 
microscopic phenotype. Malignant brain tumors on the 
other hand, are invasive with high proliferation rate and 
abnormal phenotype. Another classification by WHO 
consists of four tumor grades (I, II, III and IV).5-7 
Glioma is the most common and most fatal type of 
primary brain tumors, which affects brain’s hemispheres, 
but can also spread to brain parenchymal tissue. Glioma 
tumors are derived from glial cells and are sub-divided into 
astrocytoma, oligodendroglioma and oligoastrocytoma.8,9
Proteomics studies can be useful both in biological 
and clinical research, while one of its main applications 
is in tumor biology, which includes identifying possible 
protein biomarker candidates, diagnosis and treatment, 
pharmaceutics, protein complex analysis and drug 
target identification and studying the mechanism of 
action and possible side effects of anticancer drugs. 
Following genomics studies, proteomics also help obtain 
protein expression profiles by using two-dimensional 
electrophoresis (2DE), mass spectrometry (MS) and 
Bioinformatics tools.10-12
In the present study, used 2DE for separated proteins, 
MALDI-TOF/TOF for identified, and clustering and 
principal component analysis (PCA) for investigated 
the bata-actin expression change, is performed to obtain 
beta-actin protein expression profile in malignant human 
glioma tumor cells.
Materials and Methods
Twelve malignant human glioma tumor tissues were 
collected from excess tumor after surgical resection 
at hospital and tumors grade and malignancy was 
determined by the pathology department at the same 
hospital. Two normal tissue samples were also collected 
from the safe zone margin of tumor tissues. All collected 
samples were stored at -80°C.
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Protein Extraction
The following protocol was used for protein extraction 
and preparation from tumor tissue samples: tissue samples 
were washed by PBS, cell lysis by sonication (samples 
received 3 rounds of sonication and each round lasted 30 
seconds), acetone (50% and 100%) wash at 4°C, 15000 g, 
and three rounds of 30 minutes each. In the following, 
the obtained pellet was kept on -20°C overnight. Protein 
solubilization following acetone removal by adding 1ml 
of rehydration buffer and 50 μL of protease inhibitor to 
each protein pellet containing tubes. Finally, the Bradford 
assay was used for analysis of each tissue samples protein 
content.
Two-Dimensional Gel Electrophoresis 
Two-dimensional gel electrophoresis for protein 
separation was performed with IPG strips (18 cm) 
by isoelectric focusing (IEF). IPG trips were then 
transformed to SDS-PAGE gel and proteins were further 
separated based on their molecular weight. Followed by a 
final Coomassie blue staining of SDS-PAGE gel.
SDS-PAGE Scan and Bioinformatics Analysis
SDS-PAGE gels were scanned using scanner Densitometer 
GS-800 (BioRad) scanner at 600 dpi in tagged image 
file format (TIFF). Image MasterTM 2D platinum v6. 0 
software was then used to extract and digitize data from 
graphical images of scanned gels through detecting, 
normalizing, matching and comparing protein spots, 
according to their volume percent, followed by primary 
analysis of 2D images by Quantity One® software. The 
obtained scanned images of SDS-PAGE gels were further 
analyzed by Non-Linear Dynamics Progenesis Same 
Spot® software. After comparing the obtained 2D images 
with control samples, primary protein detection was 
performed based on the protein bands.
Mass Spectrometry Analysis 
MS was used to confirm the early protein detection results 
obtained by analysis of 2D image analysis. The identify 
of differentially expressed proteins (P < 0.05 and fold > 2) 
was established using MALDI TOF TOF MS.
Statistical Analysis, Clustering and Principal Component 
Analysis
The obtained results were statistically analyzed by t 
test and SPSS (version 19) and P < 0.05 was considered 
statistically significant. 
Protein spots with P < 0.05 were divided into 2 groups: 
increased and decreased protein expression groups. 
Then, clustering was used to identify the location 
of significantly significant spots, followed by PCA 
in determining the accuracy of the obtained results. 
Arithmetic cluster analysis was performed on two groups. 
Arithmetic cluster analysis employs correlation analysis 
to define if alterations in the levels of one individual 
protein are associated with alterations in the levels of a 
second protein across all samples (glioma and normal 
tissues). Arithmetic correlation algorithms are integral to 
the Progensis Same Spots software (Nonlinear Dynamics 
v 3.0, 2008). Multiple areas on correlation coefficients 
between protein features were calculated by Progenesis 
Same Spots and the information visually represented in 
the form of a dendrogram.
Results
Separated Protein Spots Analysis
Non-Linear Dynamics Progenesis Same Spot® software 
identified 243 spots (Figure 1A), from which 189 spots 
had P < 0.05 that contained 78% of all the spots. From 
these 189 spots, 117 spots showed differential expressions 
more than 2 fold. These 117 spots constitute 72% of the 
spots with P < 0.05 and 48% of the total spots. Differential 
Figure 1. (A) Two-dimensional Gel Electrophoresis Image, (B) Beta Actin Proteins Position Alteration in Normal Glioma Tumor Tissue. (C) Changes 
of the Beta-Actin Protein Expression in Glioma Tumor Compared to Normal Tissue.
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fold expression of all the spots with P < 0.05 are as follow: 
79 spots with less than 2 fold (42% of the spots with 
P<0.05 and 33% of the total spots). Sixty-one spots with 
2-4 fold (32% of the spots with P < 0.05 and 25% of the 
total spots). Forty-nine spots with folds more than 4 (26% 
of spots with P < 0.05 and 20% of the total spots). Twelve 
spots corresponding to beta-actin were identified with 
elevated protein expression compared to normal tissue. 
These Twelve spots and their information are presented in 
Table 1. In Figure 1B and 1C, the position and position of 
beta-actin is shown on the gel (control and tumor). Also 
in Figure 1D, Increased expression of beta actin is shown 
in relation to the initial control.
Beta-Actin Protein Spot Confirmation by MALDI-
TOF-TOF
Beta-actin protein spots were detected and confirmed 
by MALDI-TOF/TOF and the results are presented in 
Table 2.
Beta-Actin Protein Spot Confirmation by Clustering 
and Principal Component Analysis 
As illustrated in Figure 2, spots located in the red and 
blue zone represent increased and decreased expression, 
respectively. Since the beta-actin spot in located in the 
red zone, it shows elevated protein expression. In order 
to continue to further understanding of rates of change, 
each of the tumors has been compared with the controls. 
Molecular weight and isoelectric pH values are recorded 
Table 1. Gel Electrophoresis Analysis and Information About Beta-Actin Protein Expression in Malignant Glioma Tumor Tissue
Tumor Grade Sex Age
Beta Actin
P < 0.05 Fold Change PI MW (kDa)
Case 1 Glioma-astrocytoma III Man 44 2.234e-013 +2.7 7.7 42.1
Case 2 Glioma-oligodendroglioma III Man 49 2.038e-009 +2.2 7.9 42.3
Case 3 Glioma-astrocytoma III Man 66 3.329e-009 +3.1 8.1 44.9
Case 4 Glioma-GBM IV Woman 59 2.586e-009 +4.1 8.5 45.9
Case 5 Glioma-astrocytoma III Man 38 2.310e-009 +3.5 7.1 42.3
Case 6 Glioma-astrocytoma III Woman 51 4.407e-009 +2.2 7.5 40.0
Case 7 Glioma-oligodendroglioma III Man 47 2.182e-009 +2.1 7.9 42.8
Case 8 Glioma-oligodendroglioma III Man 63 5.968e-009 +2.5 7.7 43.3
Case 9 Glioma-astrocytoma III Man 69 3.253e-011 +3.3 7.9 43.6
Case 10 Glioma-astrocytoma III Woman 59 1.876e-008 +2.3 7.3 41.5
Case 11 Glioma-GBM IV Man 56 2.942e-008 +3.6 7.4 44.4
Case 12 Glioma-GBM IV Man 60 7.806e-007 +3.5 8.1 43.9
Table 2. Beta Actin Protein Matching the Same Set of Peptides by Databank
Expressed Proteins Change Fold Change Number of Peptides Score Matches Sequences Coverage
Oligodendroglioma (III) Up-Regulated 2.1-2.5 18 177 11/23 33
Astrocytoma (III) Up-Regulated 2.3-3.5 29 201 19/24 21
Astrocytoma  (IV) Up-Regulated 3.5-4.1 21 189 18/20 31
Figure 2. Diagram Scatter, Trandline Drawings for the Molecular 
Weight and Isoelectric pH, Based on Data From Table 1.
 















in Table 1, and the trend lines are shown in Figure 2. 
Afterwards, statistical analysis we have examined more 
closely, and it has been presented in Table 3 and Figure 3.
PCA was also used to confirm the accuracy of clustering. 
PCA can be used to show that there are no variances in 
the data. PCA analysis results are presented in Figure 4.
Discussion
Since proteins are the cell’s functional elements, studying 
their function and expression of transcription and 
even after their translation is important.13 Proteome 
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Table 3. Statistical Analysis of Molecular Weight and Isoelectric pH for Beta Actin
Valid Missing Mean Median Error of Mean Variance Min Max Rande
PI 12 0 7.76 7.8 0.39 0.15 7.1 8.5 1.4
MW 12 0 43.08 43.05 1.60 2.57 40 45.9 5.9
Figure 3. (A) Clustering the Proteins of Healthy and Tumor Sample 
Groups Based on Expression Changes. All these spots show significant 
expression changes in tumor tissue (P < 0.05 and fold>2). Red and 
blue zone represent increased and decreased expression, respectively. 
(B) 3D Images of Btaactin Protein.
Figure 4. (A) Principal Component Analysis of Proteins From Healthy and Tumor Tissue Based on Expression Levels. All these spots show significant 
expression changes in tumor tissue (P < 0.05 and fold>2). (A) Elevated expression compared to healthy tissue and (B) lower expression in tumor 
compared to healthy tissue. (C) For example: Beta actin protein has an up-regulation about 4.1 (fold = 4.1) in glioma-GBM (IV) brain tumors than 
normal brain tissue.
proteome analysis (including the study of biochemical 
and biophysical properties of proteomic profiles) which 
enables us to determine the role of different proteins in 
cancer initiation.14,15
Proteomics studies are performed towards different 
goals including functional studies and finding novel 
protein biomarkers for rapid diagnosis. This study was 
performed with the aim of finding possible protein 
biomarkers for early glioma tumor detection.16,17 Our 
results showed elevated expression levels of beta-actin in 
malignant glioma tumors. Beta-actin is a very common 
skeletal protein that is present almost everywhere in the 
cell and is involved in cellular movements. Beta-actin’s role 
in cellular movements affects other cellular functions as 
well including cell division, immune response and cellular 
transformation.18-21 Based on beta-actin’s importance in 
cell function, proteomics investigations can be useful in 
better understanding and finding a biomarker candidate 
for malignant glioma. It is important to know when a cell 
is transformed and when it becomes malignant.22,23 Here 
we evaluated the beta-actin expression in malignant cells. 
Our results indicate that beta-actin expression control 
is controlled intracellularly since its expression levels 
differ with cell type and situation. Previous studies have 
indicated that tumor cell’s malignancy is related to actin 
polymers. Despite no standard has been determined yet, 
all types of tumor cells show common cellular movements 
involving beta-actin protein.24
(the whole protein content of a genome) is related to 
different diseases. Studying the proteome is critical in 
order to achieve a novel system based on proteins for 
disease prognosis, prevention and treatment. Cancer cells 
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Nebl and colleagues studies on beta-actin showed that 
cell’s skeletal proteins including actin fibers affect lipid 
rafts in the cell membrane. Lipid rafts play an important 
role in the membranes fluidity which in turn affects 
cellular pathogenicity.25,26
Proteomics analysis has identified several proteins 
involved in oxidative stress response. Beta-actin is an 
abundant important protein in the glutathionylation 
process following oxidative stress. The first cellular 
response results in superoxide generation which can 
eventually results in cellular transformation.27-30
A cell needs to undergo specific structural changes 
in order to become malignant. Increase in beta-actin 
levels is related to invasiveness, including its effects on 
the carcinogen, primary and secondary GBM.31,32 In this 
situation, beta-actin polymerization results in an invasive 
structure which affects cellular movements and can lead 
to invasiveness and malignancy.33,34
There are a large number of studies in the literature on 
beta-actin’s role in different types of cancer and gliomas, 
including the studies of Fages et al, Ziv-Av et al and 
Panopoulos and colleagues which are all confirm our 
results on the effect of increased beta-actin expression 
in different types of cancer including glioma. However, 
different folding is reported by these groups and us.35-37
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